Next session. Hormones.
First speaker Prof Alfred Mueck.
Principles to select estrogens.
Conjugated equine estrogens - contain a lot of substances, in variable amounts.
Suggests we move away from its use. #IMS2022
Estradiol containing COCPs. Took a while to develop because of bleeding issues.
Now we have pills with good cycle control, because of the progestogen. Dienogest or nomegestrol. #IMS2022
Next speaker Prof Nick Panay. (UK)
Optimizing hormone therapy through choice of progestogen/progesterone. #IMS2022
Observational data suggest that type of progestogen has an impact on risk of breast cancer. Micronised progesterone not associate with inc risk up to 5 yrs of use. #IMS2022
Micronised progesterone may have neutral effect on CV system but more information needed. #IMS2022
What are the options for women with progestogen/progesterone intolerance?
Some research going on with (off label) use of low dose LNG IUS with regular endometrial surveillance. #IMS2022
Conclusion. Not all progestogens are the same. #IMS2022
Final speaker. Prof Andrea Genazzani (Italy).
Behind estrogens and progesterone: Menopause and neurosteroids. #IMS2022
Last day of IMS.
Debate: are we over-treating with hormone therapy?
First speaker Prof Martha Hickey (Australia)
For the motion. #IMS2022
Argues that the only primary indication for MHT is VMS (not mood, not sleep and not for primary prevention of disease).
Quotes US preventive task force.
Discusses Collaborative group on hormonal factors in breast cancer. (Lancet)
Observational study. #IMS2022
Final plenary for today.
The microbiome: endocrine nexus in human health.
Prof Jack Gilbert (US). #IMS2022
Our immune system regulates our microbiome.
Can be in a state of homeostasis or dysbiosis.
Dysbiosis can lead to diseases.
During menopause a reduction in microbiome diversity tends to occur.
Can affect hormones and metabolic factors eg lipids, and weight.
May affect brain chemistry and mood too.#IMS2022
IMS symposium on CVD at midlife.
First speaker Prof Chrisandra Shufelt (USA).
MHT and CVD: looking back before moving forward.
KEEPS looked transdermal vs oral estrogen, using annual CIMT. No sigt diff. #IMS2022
ELITE looked at CIMT in groups <6 or >10 yrs post menopause. Increase in CIMT was lower in the early menopause group but not at a level to affect relative risk for CVD. #IMS2022
IMS Congress day 3.
Starting very early with concurrent presentations from menopause societies.
AMS presentation on Menopause and work.
Chaired by Dr Sylvia Rosevear (Aotearoa/NZ). menopause.org.au
I was the first speaker.
Case studies in menopause at work.
I began by acknowledging that some people who experience menopause don’t identify as women. Gender diverse people can also experience menopause. #IMS2022
Whether a workplace is menopause supportive or not can make the difference between someone staying in their workplace or leaving.
This in turn can have long term impacts including on life trajectory, and retirement income. #IMS2022
I’ll be tweeting when I can from the International Menopause Society Congress. #IMS2022
Starting with the meeting before the meeting.
The Council of Affiliated Menopause Societies.
Societies from around the world connecting and collaborating.
Welcome from IMS President Steven Goldstein. #IMS2022
New CAMS chair Dr Duru Shah pointing out that the number of women over 60 is expected to double by 2050.
UN priority is to reduce health inequities and ageism and promote healthy aging.